Chordia Therapeutics (190A) · FactRestated
Single segment consisting solely of the pharmaceutical business
First written in FY2024-Q3. 3 of 4 entries say "Restated". Latest entry: FY2026-H1.
4entries
3years
0from disclosures
How it moved
Same theme, other companies
Single-segment structure focused on the Pharmaceutical BusinessA theme 11 companies write about · 0 as a headwind · 6 as a tailwind
10 other companies' latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2026-H1RestatedAnnual report
「Because the company operates in a single segment consisting solely of the pharmaceutical business, segment-by-segment operating results are not presented.」
The business structure consisting of a single segment focused solely on the pharmaceutical business remains unchanged. - FY2025-H1RestatedAnnual report
「Because the company operates in a single segment consisting solely of the pharmaceutical business, segment-by-segment operating results are not presented.」
The business structure consisting of a single segment focused solely on the pharmaceutical business remains unchanged. - FY2024RestatedAnnual report
「As the Company's business consists of a single segment, the pharmaceutical business, it does not provide disclosures by segment.」
The business structure consisting of a single segment focused solely on the pharmaceutical business remains unchanged. - FY2024-Q3First statedAnnual report
「Because the company operates in a single segment consisting solely of the pharmaceutical business, segment-by-segment operating results are not presented.」
The business segment consists solely of the pharmaceutical business.